Balaji Amines Q2 FY26 results: Revenue and profit decline year-on-year

Revenue DeclineEbitda Margin CompressionResults View source PDF Explain this filing

BALAMINES · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.9%Reaction day

₹1360.00

prior close

₹1345.70

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.3%-4.6% vs market

Specialty Chemicals peers, median of 86sector-0.8%-4.0% vs sector

On the reaction day the stock moved 4.6 pts less than Nifty Microcap 250 and 4.0 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-3.4

10m

-2.8

15m

-3.1

30m

-3.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.9-0.3-4.6-0.8-4.0

Next day

-6.9+0.7-7.6+0.4-7.4

-7.6+0.6-8.2-0.2-7.4

-9.9+0.5-10.4-1.0-8.9

-10.5+1.1-11.6-0.8-9.6

-12.2+0.3-12.5-2.0-10.2

-11.9-0.2-11.7-2.9-9.0

15d

-15.6-2.2-13.3-4.7-10.9

-15.8-4.9-10.9-6.4-9.4

-18.9-7.5-11.5-9.6-9.3

-17.9-4.8-13.2-9.4-8.5

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 86Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved unaudited Q2 and H1 FY26 results ended Sep 30, 2025. Standalone revenue from operations fell to Rs 309.20 cr in Q2 from Rs 310.96 cr YoY. H1 standalone revenue declined to Rs 628.58 cr from Rs 652.80 cr; PAT dropped to Rs 71.25 cr from Rs 80.92 cr. Consolidated H1 revenue was Rs 698.89 cr versus Rs 731.63 cr; PAT at Rs 73.63 cr versus Rs 87.01 cr. EPS at Rs 22.39 consolidated. Limited review by M Anandam and Co.

Likely market impact

Revenue and profit slipped versus last year. Operating cash flow also weakened. Investors may watch specialty chemicals demand outlook.